Melanoma Clinical Trials in New York

Showing 21-40 of 331 trials

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

NCT06425926

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

Melanoma Stage IVSolid Tumor

Georgiamune Inc117 participantsStarted May 2024

Scottsdale, Arizona, United States • Bakersfield, California, United States • Fullerton, California, United States +8 more locations

Active Not RecruitingPhase 1< 1 mile

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

NCT05571839

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.

Cutaneous MelanomaNon-small Cell Lung CancerColorectal Neoplasms+2 more

Seagen, a wholly owned subsidiary of Pfizer41 participantsStarted Jan 2023

Los Angeles, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +33 more locations

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Melanoma Trials in Other Cities

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Dinaciclib in Treating Patients With Stage IV Melanoma

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Other Conditions in New York